Rezdiffra Real-World Data to Show Liver Gains
Adults with MASH and liver fibrosis will see new real-world results on this once-daily treatment in Denver.
Updated on Nov. 2, 2026 in Diabetes
Madrigal Pharmaceuticals will present new real-world research on Rezdiffra, a once-daily oral medication for liver disease, at a medical conference in Denver beginning November 5. The presentations include 13 abstracts from its RESONANCE real-world evidence program, drawing on data from more than 12,000 patients, relevant to adults with noninvasive liver fibrosis.
Why it matters
Rezdiffra was the first medication approved for MASH in the United States and Europe, so how it performs across a broad, real-world patient population helps clinicians and patients understand its role in managing the condition. The research is also relevant to the company's commercialization strategy as it seeks to show benefit beyond controlled clinical trials.
The findings come from real-world evidence analyses of more than 12,000 patients, examining changes in noninvasive measures of liver health over as long as 12 months. Among patients receiving the 100-milligram dose, 91% showed improvement or stabilization of liver stiffness at one year, though this is observational data rather than a controlled trial.
The players
Madrigal Pharmaceuticals
A pharmaceutical company focused on liver disease, best known for developing Rezdiffra, the first approved treatment for MASH in the United States and Europe.
AASLD Liver Meeting
The annual meeting of the American Association for the Study of Liver Diseases, a major forum where hepatology research and clinical findings are presented.
The details
Rezdiffra, also known as resmetirom, is a once-daily oral medication that targets thyroid hormone receptor beta in the liver. It is approved for adults with noncirrhotic MASH and moderate to advanced liver fibrosis, stages F2 to F3. The analyses use noninvasive measures to track liver health changes over time, offering a way to monitor disease progression without repeated biopsies.
Timeline
November 5-9: AASLD Liver Meeting, where Madrigal presents its RESONANCE abstracts.
November 5: The medical conference in Denver begins with Madrigal's presentations.
Health Landscape
Rezdiffra's approval marked the first treatment option for MASH in the United States and Europe, a condition with no previously approved drug therapies. These real-world results add population-level evidence to that early clinical experience as the field works to establish long-term outcomes for patients with liver fibrosis.
If you have been diagnosed with MASH or fatty liver disease with fibrosis, these findings may be worth discussing with your doctor as part of understanding treatment options. Because Rezdiffra is not approved for cirrhosis, anyone with more advanced liver disease should review eligibility with their physician.
The takeaway
Real-world data from more than 12,000 patients adds to the evidence on how a liver-focused treatment performs outside clinical trials. If you are managing fatty liver disease, ask your physician whether monitoring liver stiffness with noninvasive tests is part of your care plan.
What happens next
Madrigal's RESONANCE abstracts are scheduled for presentation at the AASLD Liver Meeting from November 5 to 9, 2026.
Further reading
For more on the metabolic conditions linked to liver disease, explore our Diabetes coverage.
Source note: This article includes information reported by MyChesCo.
